153 related articles for article (PubMed ID: 9021435)
1. Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline.
Mascher HJ; Kikuta C; Millendorfer A; Schiel H; Ludwig G
Int J Clin Pharmacol Ther; 1997 Jan; 35(1):9-13. PubMed ID: 9021435
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability of two selegiline hydrochloride tablet products.
Müller FO; Schall R; Hundt HK; Joubert A; Middle MV; Muir AR; Duursema L; Groenewoud G; Swart KJ
Arzneimittelforschung; 1996 Nov; 46(11):1037-40. PubMed ID: 8955861
[TBL] [Abstract][Full Text] [Related]
3. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding.
Laine K; Anttila M; Huupponen R; Mäki-Ikola O; Heinonen E
Clin Neuropharmacol; 2000; 23(1):22-7. PubMed ID: 10682227
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline.
Chen L; Shen B; Wang S; Yu Y; Yan H; Shi Y; Duan G; Xiang P
Drug Test Anal; 2019 Jun; 11(6):898-905. PubMed ID: 30614204
[TBL] [Abstract][Full Text] [Related]
5. Gas chromatographic procedure for simultaneous determination of selegiline metabolites, amphetamine, methamphetamine and demethyl-deprenyl in pig plasma.
Szebeni G; Lengyel J; Székács G; Magyar K; Gaál J; Szatmári I
Acta Physiol Hung; 1995; 83(2):135-41. PubMed ID: 8588500
[TBL] [Abstract][Full Text] [Related]
6. Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.
Barrett JS; Szego P; Rohatagi S; Morales RJ; De Witt KE; Rajewski G; Ireland J
Pharm Res; 1996 Oct; 13(10):1535-40. PubMed ID: 8899847
[TBL] [Abstract][Full Text] [Related]
7. Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl).
Waitzinger J; Ludwig G; Pabst G; Michaelis K; Reh C
Int J Clin Pharmacol Ther; 1996 Oct; 34(10):427-32. PubMed ID: 8897080
[TBL] [Abstract][Full Text] [Related]
8. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 polymorphism is not crucial for the disposition of selegiline.
Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L
Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797
[TBL] [Abstract][Full Text] [Related]
10. Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline.
Palovaara S; Anttila M; Nyman L; Laine K
Eur J Clin Pharmacol; 2002 Jul; 58(4):259-63. PubMed ID: 12136372
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse.
Magyar K; Szatmáry I; Szebeni G; Lengyel J
J Neural Transm Suppl; 2007; (72):165-73. PubMed ID: 17982891
[TBL] [Abstract][Full Text] [Related]
12. CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline.
Laine K; Anttila M; Nyman L; Wahlberg A; Bertilsson L
Eur J Clin Pharmacol; 2001 May; 57(2):137-42. PubMed ID: 11417445
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.
Azzaro AJ; Ziemniak J; Kemper E; Campbell BJ; VanDenBerg C
J Clin Pharmacol; 2007 Oct; 47(10):1256-67. PubMed ID: 17715422
[TBL] [Abstract][Full Text] [Related]
14. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.
Kivistö KT; Wang JS; Backman JT; Nyman L; Taavitsainen P; Anttila M; Neuvonen PJ
Eur J Clin Pharmacol; 2001 Apr; 57(1):37-42. PubMed ID: 11372588
[TBL] [Abstract][Full Text] [Related]
15. Stereoselective analyses of selegiline metabolites: possible urinary markers for selegiline therapy.
Hasegawa M; Matsubara K; Fukushima S; Maseda C; Uezono T; Kimura K
Forensic Sci Int; 1999 Apr; 101(2):95-106. PubMed ID: 10371041
[TBL] [Abstract][Full Text] [Related]
16. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration.
Rohatagi S; Barrett JS; DeWitt KE; Morales RJ
Biopharm Drug Dispos; 1997 Oct; 18(7):567-84. PubMed ID: 9330778
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system.
Rohatagi S; Barrett JS; DeWitt KE; Lessard D; Morales RJ
Biopharm Drug Dispos; 1997 Nov; 18(8):665-80. PubMed ID: 9373724
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline.
Newton TF; De La Garza R; Fong T; Chiang N; Holmes TH; Bloch DA; Anderson A; Elkashef A
Pharmacol Biochem Behav; 2005 Dec; 82(4):704-11. PubMed ID: 16413604
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and bioequivalence evaluation of 2 levosulpiride preparations after a single oral dose in healthy male Korean volunteers.
Cho HY; Moon JD; Lee YB
Int J Clin Pharmacol Ther; 2004 Mar; 42(3):174-80. PubMed ID: 15049438
[TBL] [Abstract][Full Text] [Related]
20. Methamphetamine and amphetamine derived from the metabolism of selegiline.
Romberg RW; Needleman SB; Snyder JJ; Greedan A
J Forensic Sci; 1995 Nov; 40(6):1100-2. PubMed ID: 8522918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
